Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on "Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a"

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 6, 2013, Pages

  Ye, Yumei ^a   Birnbaum, Yochai ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPYRIDAMOLE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SOMATOMEDIN C; UNCLASSIFIED DRUG; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; VENOM;

APOPTOSIS; ATTENUATION; BRAIN ISCHEMIA; CELL PROTECTION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEMOGLOBIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; TRANSIENT ISCHEMIC ATTACK; UNFOLDED PROTEIN RESPONSE; ANIMAL; DRUG EFFECT; METABOLISM; NOTE; PHYSIOLOGY;

ANIMALS; APOPTOSIS; ENDOPLASMIC RETICULUM STRESS; MYOCYTES, CARDIAC; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84877280491     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00419.2012     Document Type: Editorial

References (14)

1. Birnbaum Y, Castillo AC, Qian J, Ling S, Ye H, Perez-Polo JR, Bajaj M, Ye Y. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther 26: 445-456, 2012.
2. Birnbaum Y, Ye Y, Bajaj M. Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord 10: 387-390, 2012.
3. Gwathmey JK, Yerevanian AI, Hajjar RJ. Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol 50: 803-812, 2011.
4. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Green-berg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ. Calcium upregu-lation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 15: 171-181, 2009.
5. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 57: 1169-1180, 2011.
6. Kim SJ, Abdellatif M, Koul S, Crystal GJ. Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway. Am J Physiol Heart Circ Physiol 295: H130-H135, 2008.
7. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ, Uretsky BF, Birnbaum Y. The cardiopro-tective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 21: 321-330, 2007.
8. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 14: 255-263, 2009.
9. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J Diabetes 4: 55-67, 2012.
10. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298: H1454-H1465, 2010.
11. Ye Y, Long B, Qian J, Perez-Polo JR, Birnbaum Y. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc Drugs Ther 24: 391-399, 2010.
12. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Ba-sic Res Cardiol 106: 925-952, 2011.
13. Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR, Bajaj M, Birnbaum Y. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 304: H131-H141, 2013.
14. Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol (January 9, 2013). doi:10.1152/ajpcell.00248.2012.